Evidence map›Paper›PMID 25587068›Full record

ArticleJournal of the American Society of Nephrology : JASN2015

MicroRNA-687 Induced by Hypoxia-Inducible Factor-1 Targets Phosphatase and Tensin Homolog in Renal Ischemia-Reperfusion Injury.

Kirti Bhatt, Qingqing Wei, Navjotsingh Pabla, Guie Dong, Qing-Sheng Mi, Mingyu Liang, Changlin Mei, Zheng Dong

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 112 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Role of miRNAs in macrophage-mediated kidney injury.Pediatric nephrology (Berlin, Germany) · 2024
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. PFKFB3 mediates tubular cell death in cisplatin nephrotoxicity by activating CDK4.Translational research : the journal of laboratory and clinical medicine · 2023
    Article
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Kirti BhattDepartment of Cellular Biology and Anatomy, Georgia Regents University and Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia;
Qingqing WeiDepartment of Cellular Biology and Anatomy, Georgia Regents University and Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia;
Navjotsingh PablaDepartment of Cellular Biology and Anatomy, Georgia Regents University and Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia;
Guie DongDepartment of Cellular Biology and Anatomy, Georgia Regents University and Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia;
Qing-Sheng MiDepartments of Dermatology and Internal Medicine, Henry Ford Health System, Detroit, Michigan;
Mingyu LiangDepartment of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin;
Changlin MeiDepartment of Nephrology, Changzheng Hospital, Second Military Medical University, Shanghai, China; and.
Zheng DongDepartment of Cellular Biology and Anatomy, Georgia Regents University and Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia; Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China zdong@gru.edu.
Augusta University · USCentral South University · CNHenry Ford Health System · USMedical College of Wisconsin · US

Funding

DNA methylation in kidney repair after ischemic AKIR01DK058831 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI DONG, ZHENG · 2001 to 2025
$7.5M
Kidney Injury by Cisplatin and Renoprotective Strategies.R01DK087843 · NIDDK · AUGUSTA UNIVERSITY · PI DONG, ZHENG · 2010 to 2025
$5.8M
Regulatory RNA in Hypertension and Renal InjuryR01HL121233 · NHLBI · UNIVERSITY OF ARIZONA · PI MINGYU LIANG · 2014 to 2026
$3.8M
Molecular Regulation of Ischemic Renal FailureI01BX000319 · VA · CHARLIE NORWOOD VA MEDICAL CENTER · PI Zheng Dong · 2009 to 2026
–
BLRD VA I01 BX000319NHLBI NIH HHS R01 HL121233NIDDK NIH HHS R01 DK058831NIDDK NIH HHS R01 DK087843
6 · The paper itself

Abstract

Ischemia-reperfusion injury contributes to tissue damage and organ failure in clinical settings, but the underlying mechanism remains elusive and effective therapies are still lacking. Here, we identified microRNA 687 (miR-687) as a key regulator and therapeutic target in renal ischemia-reperfusion injury. We show that miR-687 is markedly upregulated in the kidney during renal ischemia-reperfusion in mice and in cultured kidney cells during hypoxia. MiR-687 induction under these conditions was mediated by hypoxia-inducible factor-1 (HIF-1). Upon induction in vitro, miR-687 repressed the expression of phosphatase and tensin homolog (PTEN) and facilitated cell cycle progression and apoptosis. Blockade of miR-687 preserved PTEN expression and attenuated cell cycle activation and renal apoptosis, resulting in protection against kidney injury in mice. Collectively, these results unveil a novel HIF-1/miR-687/PTEN signaling pathway in ischemia-reperfusion injury that may be targeted for therapy.

Indexed as

Analysis of VarianceAnimalsBlotting, NorthernDisease Models, AnimalHypoxia-Inducible Factor 1, alpha SubunitKidney DiseasesMiceMice, Inbred C57BLMicrofilament ProteinsMicroRNAsPTEN PhosphohydrolaseRandom AllocationReal-Time Polymerase Chain ReactionReperfusion InjurySignal TransductionTensinsHypoxia-Inducible Factor 1, alpha SubunitMicrofilament ProteinsMicroRNAsPTEN PhosphohydrolasePten protein, mouseTensinsacute renal failurecell deathhypoxiaischemia-reperfusionrenal injury

Identifiers

PMID25587068
PMCPMC4483585
OpenAlexW1965518526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.